Compare DRCT & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRCT | PHGE |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | 57 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 9.2M |
| IPO Year | 2021 | N/A |
| Metric | DRCT | PHGE |
|---|---|---|
| Price | $0.76 | $4.68 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $330.00 | N/A |
| AVG Volume (30 Days) | ★ 113.3K | 65.7K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $62,288,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $58.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.04 | $0.25 |
| 52 Week High | $6.04 | $8.50 |
| Indicator | DRCT | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 34.68 | 42.86 |
| Support Level | $0.50 | $4.00 |
| Resistance Level | $0.79 | $5.99 |
| Average True Range (ATR) | 0.08 | 0.76 |
| MACD | -0.00 | -0.18 |
| Stochastic Oscillator | 13.86 | 4.50 |
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).